Assessment of Botulinum Toxin Type A in the Treatment of Hand Eczema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201704002194318

Enrollment

Registered

2017-04-11

Start date

2017-04-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases Hand Eczema

Interventions

BTXA

Standard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Active symptomatic palmar hand eczema. Bilateral involvement.

Exclusion criteria

Exclusion criteria: Skin infection at the site of injection. History of use of botulinum toxin in the last 4 months. Pregnancy, lactation in females. Any contraindication to botulinum toxin injection including associated disorder that may affect the neuromuscular function like myasthenia gravis and Lambert-Eaton disease. History of previous allergy to BTXA.

Design outcomes

Primary

Measure	Time frame
Visual linear analog scale of pruritus.	—

Secondary

Measure	Time frame
Hand eczema severity index	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com002-01223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026